Novavax (NVAX, $124.45) launches Phase 3 trial in the US
Biotech company Novavax announced that it is launching a Phase III trial of its covid-19 vaccine candidate in the U.S. and Mexico.
Two-thirds of the participants in the trial will randomly receive two intramuscular injections of the vaccine, administered 21 days apart, while one-third of the trial participants will receive a placebo.
The company said that it has selected around 100 trial sites in the U.S.
According to the statement from the company, Phases 1 and 2 trials of the vaccine candidate revealed that it was created a robust immune response. It also suggested a good tolerance generally.
Novavax is also currently conducting a large Phase 3 clinical study in the United Kingdom (U.K.), a Phase 2b safety and efficacy study in South Africa, and an ongoing Phase1/2 trial in the U.S. and Australia. Results from these trials are expected to come in as soon as early first quarter 2021, although timing could depend on transmission rates in the regions.
NVAX in upward trend: 10-day moving average crossed above 50-day moving average on January 08, 2026
The 10-day moving average for NVAX crossed bullishly above the 50-day moving average on January 08, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on December 22, 2025. You may want to consider a long position or call options on NVAX as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
NVAX moved above its 50-day moving average on January 05, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where NVAX advanced for three days, in of 249 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 111 cases where NVAX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for NVAX moved out of overbought territory on January 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The 50-day moving average for NVAX moved below the 200-day moving average on December 23, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVAX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
NVAX broke above its upper Bollinger Band on January 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NVAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (32.468) is normal, around the industry mean (30.117). P/E Ratio (4.562) is within average values for comparable stocks, (51.336). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.894). Dividend Yield (0.000) settles around the average of (0.058) among similar stocks. P/S Ratio (1.432) is also within normal values, averaging (320.472).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in development of novel recombinant vaccines
Industry Biotechnology
Advertisement